Ultragenyx Pharmaceutical (RARE) Gross Profit (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) has 9 years of Gross Profit data on file, last reported at $106.0 million in Q1 2026.

• Gross Profit for Q1 2026 came in at $106.0 million, down 3.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $559.4 million (up 11.49% YoY), and the FY2025 annual result was $564.0 million, up 16.77% from the prior year.
• Gross Profit eased to $106.0 million in Q1 2026 per RARE's latest filing, from $177.9 million in the prior quarter.
• Over five years, Gross Profit peaked at $177.9 million in Q4 2025 and troughed at $73.8 million in Q1 2022.
• A 5-year average of $110.4 million and a median of $106.0 million in 2026 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2022 and 2024: Gross Profit retreated 21.62% in 2022, then surged 36.07% in 2024.
• A 5-year view of Gross Profit shows it stood at $98.0 million in 2022, then increased by 17.62% to $115.3 million in 2023, then advanced by 27.91% to $147.5 million in 2024, then gained by 20.65% to $177.9 million in 2025, then tumbled by 40.43% to $106.0 million in 2026.
• Business Quant data shows RARE's Gross Profit at $106.0 million in Q1 2026, $177.9 million in Q4 2025, and $131.9 million in Q3 2025.